We investigated the expression of MAGE genes in 10 renal cell carcinom
a (RCC) cell lines, 50 RCC tumor samples and 5 normal kidney samples u
sing reverse transcription-polymerase chain reaction (RT-PCR). MAGE-1,
-2, -3 and -4 genes were expressed in 4, 1, 10 and 3 of 10 RCC cell l
ines, respectively, and 11, 8, 38 and 15 of 50 RCC samples. In contras
t, there was no expression of MAGE genes detected in any of the normal
kidneys. The incidence of the expression of plural MAGE genes in high
stage RCC was significantly higher than that in low stage RCC. An ana
lysis based on clinicopathological factors revealed that MAGE-4 gene w
as more frequently expressed in clear cell subtype than in granular ce
ll subtype RCCs. Our results suggest that owing to the high incidence
of MAGE gene expression in RCC, a large proportion of patients could b
e suitable candidates for novel immune therapies involving tumor-speci
fic antigens encoded by MAGE genes.